Published CONNEX phase 3 program
Open this page in the complete interactive Atlas
Reports individual and pooled findings from the three 26-week randomized trials.
Where this source fits
Iclepertin · Cognitive impairment associated with schizophrenia
Over 26 weeks, the pooled difference on the standardized cognitive battery was 0.13 T-score points, with a 95% confidence interval from −0.40 to 0.65. No meaningful cognitive advantage emerged.
The outcome was cognition, including capacities such as attention and memory. These results do not test treatment of hallucinations or catatonia.
Reading basis · Original source summarized in the experimental-drug section